Subtopic Deep Dive
Tyrosine Kinase Inhibitor Resistance Mechanisms
Research Guide
What is Tyrosine Kinase Inhibitor Resistance Mechanisms?
Tyrosine kinase inhibitor resistance mechanisms are genetic and phenotypic changes in EGFR-mutant lung cancers that confer acquired resistance to EGFR and ALK TKIs through mutations like T790M, MET amplification, and histological transformation.
Over 155 patients with EGFR-mutant lung cancers showed diverse resistance mechanisms including T790M mutation in 60%, MET amplification in 5%, and small cell transformation in 5% (Yu et al., 2013, 2430 citations). The T790M gatekeeper mutation increases EGFR kinase affinity for ATP, reducing TKI binding efficacy (Yun et al., 2008, 2062 citations). Osimertinib targets T790M-resistant cases but faces secondary resistance challenges (Jänne et al., 2015, 2078 citations).
Why It Matters
Understanding TKI resistance guides next-generation inhibitors like osimertinib, extending progression-free survival in EGFR-mutant NSCLC from 10 to 18 months (Soria et al., 2017, 4982 citations). Yu et al. (2013) analysis of 155 resistance specimens informs combination therapies targeting MET or histologic shifts. Vasan et al. (2019) framework on cancer drug resistance impacts trial design for polyclonal evolution, improving overall survival as seen in osimertinib first-line use (Ramalingam et al., 2019, 2641 citations).
Key Research Challenges
Polyclonal Resistance Evolution
Tumors develop heterogeneous subclones with T790M, MET amp, or transformations, complicating uniform therapy (Yu et al., 2013). Single-cell sequencing reveals branching evolution but lacks clinical scalability. Liquid biopsies detect ctDNA but miss spatial heterogeneity.
T790M Mutation Persistence
T790M boosts ATP affinity, evading first/third-generation TKIs (Yun et al., 2008). Osimertinib overcomes it initially but triggers C797S emergence (Jänne et al., 2015). No universal post-osimertinib strategy exists.
Histological Transformation Detection
EGFR-mutant adenocarcinomas transform to small cell or squamous, bypassing TKI dependence (Yu et al., 2013). Repeat biopsies are invasive; imaging biomarkers underdeveloped. Travis et al. (2011) classification aids diagnosis but resistance context lags.
Essential Papers
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
David Cunningham, Yves Humblet, Salvatore Siena et al. · 2004 · New England Journal of Medicine · 5.0K citations
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · 2017 · New England Journal of Medicine · 5.0K citations
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adv...
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · 2019 · New England Journal of Medicine · 2.6K citations
Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The s...
A view on drug resistance in cancer
Neil Vasan, José Baselga, David M. Hyman · 2019 · Nature · 2.6K citations
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · 2013 · Clinical Cancer Research · 2.4K citations
Abstract Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified various m...
Reading Guide
Foundational Papers
Start with Yun et al. (2008) for T790M mechanism, then Yu et al. (2013) for clinical resistance spectrum in 155 patients, and Travis et al. (2011) for adenocarcinoma classification context.
Recent Advances
Study Soria et al. (2017) and Ramalingam et al. (2019) for osimertinib efficacy OS data, Jänne et al. (2015) for T790M targeting, and Vasan et al. (2019) for resistance frameworks.
Core Methods
Repeat tumor biopsy/liquid biopsy for NGS (Yu et al., 2013); crystallography for mutation kinetics (Yun et al., 2008); ctDNA monitoring for clonal dynamics.
How PapersFlow Helps You Research Tyrosine Kinase Inhibitor Resistance Mechanisms
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to query 'EGFR T790M resistance mechanisms lung cancer' yielding Yu et al. (2013) as top hit with 2430 citations, then citationGraph maps 500+ downstream papers on osimertinib resistance, and findSimilarPapers links to Yun et al. (2008) for mechanistic insights.
Analyze & Verify
Analysis Agent applies readPaperContent to extract resistance frequencies from Yu et al. (2013), verifies T790M ATP affinity claims via verifyResponse (CoVe) against Yun et al. (2008), and runs PythonAnalysis on mutation prevalence data with pandas for statistical tests (e.g., chi-square on 155-patient cohorts), graded A via GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps like post-osimertinib strategies via contradiction flagging across Jänne et al. (2015) and Ramalingam et al. (2019); Writing Agent uses latexEditText for mechanism diagrams, latexSyncCitations for 20-paper bibliography, latexCompile for review manuscript, and exportMermaid for resistance pathway flowcharts.
Use Cases
"Quantify T790M frequency in EGFR TKI resistance cohorts."
Research Agent → searchPapers('T790M EGFR resistance') → Analysis Agent → readPaperContent(Yu 2013) → runPythonAnalysis(pandas chi-square on 155-patient data) → CSV export of prevalence stats.
"Draft LaTeX review on osimertinib resistance mechanisms."
Synthesis Agent → gap detection(Jänne 2015 + Soria 2017) → Writing Agent → latexEditText('resistance section') → latexSyncCitations(10 papers) → latexCompile → PDF output with cited figures.
"Find code for simulating TKI resistance evolution."
Research Agent → paperExtractUrls(Yu 2013) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on evolution simulation scripts.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ TKI resistance papers) → citationGraph → DeepScan(7-step verify on Yu 2013 mechanisms) → structured report on polyclonal patterns. Theorizer generates hypotheses like 'MET amp + T790M co-occurrence predicts osimertinib failure' from Vasan et al. (2019) + Jänne et al. (2015), validated via CoVe. DeepScan analyzes single-paper claims with runPythonAnalysis on mutation data checkpoints.
Frequently Asked Questions
What is the primary mechanism of EGFR TKI resistance?
T790M gatekeeper mutation occurs in 60% of cases, increasing ATP affinity and evading TKIs (Yun et al., 2008; Yu et al., 2013).
How was resistance systematically characterized?
Yu et al. (2013) biopsied 155 EGFR-mutant NSCLC patients post-TKI, finding T790M (60%), MET amp (5%), EGFR amp (5%), small cell transformation (5%).
What key paper defines T790M biophysics?
Yun et al. (2008) crystallized EGFR T790M, showing 20-fold ATP affinity increase causing resistance (2062 citations).
What are open problems in TKI resistance?
Post-osimertinib C797S mutations, polyclonal tracking via liquid biopsy, and universal combination therapies remain unsolved (Jänne et al., 2015; Vasan et al., 2019).
Research Lung Cancer Treatments and Mutations with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tyrosine Kinase Inhibitor Resistance Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers